Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID03779009

Minimally INvasive Colon Cancer Surgery Through IMmunomics and Optical Mapping of the Sentinel Lymph Node.

Led by University Hospital, Ghent · Updated on 2024-09-19

70

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

U

University Hospital, Ghent

Lead Sponsor

K

Kom Op Tegen Kanker

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the use of laparoscopic fluorescent imaging to detect the sentinel lymph node (SLN) during surgery in patients with colon cancer. This study aims to explore the immune and microenvironmental changes in normal and affected lymph nodes and link these changes to their anatomical locations. The goal is to improve the understanding and surgical management of colon cancer by mapping lymph node involvement precisely. The study involves injecting a tracer called ICG-nanocoll, which is indocyanine green combined with human albumin particles, into the tissue near the tumor during laparoscopic surgery. After injection, near-infrared fluorescence imaging is used to identify and mark the sentinel lymph nodes. This procedure helps surgeons visually map the nodes during the operation to assess tumor involvement. Participants will undergo surgery with the tracer injection and imaging. Researchers will monitor the tumor status of the sentinel lymph node and other lymph nodes for up to one month after surgery. Additionally, immunological markers will be studied for up to 12 months after surgery. The study includes regular laboratory tests and clinical evaluations to track outcomes and safety over time, with the entire participation lasting up to a year after the operation.

CONDITIONS

Brief Title

Minimally INvasive Colon Cancer Surgery Through IMmunomics and Optical Mapping of the Sentinel Lymph Node.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Proven adenocarcinoma of the colon
  • Clinically node negative (stage II) non-metastatic colon cancer
  • Locally resectable disease
  • Adequate mental ability to understand treatment and give consent
  • Serum creatinine 64 1.5 mg/dl or GFR 7 60 mL/min/1.73 m2
  • Serum total bilirubin 64 1.5 mg/dl except Gilbert's disease
  • Platelet count > 100,000/bcl
  • Hemoglobin > 9g/dl
  • Neutrophil granulocytes > 1,500/ml
  • INR 64 2
  • No alcohol or drug abuse
  • Not enrolled in other conflicting trials
  • No current chronic systemic immune therapy, chemotherapy, or hormone therapy
  • No severe organ insufficiency
  • Not pregnant or breastfeeding
  • Use of adequate contraception if fertile
  • Provided written informed consent
Not Eligible

You will not qualify if you...

  • Node positive and/or metastatic disease
  • Locally unresectable disease
  • Medically unfit with Karnofsky index < 70%
  • Allergy to iodides or products containing human albumin
  • Pregnancy or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Day of surgery and immediate recovery period

Participants undergo minimally invasive colon cancer surgery with injection of ICG-nanocoll tracer to identify and mark sentinel lymph nodes using near infrared fluorescence imaging.

1 surgical visit and immediate post-operative care

Post-operative Follow-up

Duration - Up to 1 month after surgery

Participants are monitored for tumor status of sentinel lymph nodes and other lymph nodes up to 1 month after surgery.

Approximately 3 to 4 follow-up visits

Long-term Monitoring

Duration - Up to 12 months after surgery

Participants are monitored for immunological markers for up to 12 months after surgery.

Periodic visits over 12 months

Trial Site Locations

Total: 1 location

1

Ghent University Hospital

Ghent, Belgium, 9000

Actively Recruiting

Loading map...

Research Team

W

Wim Ceelen

S

Sarah Cosyns

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Similar Trials

A Manualized Post-Traumatic Growth Intervention for People W...

Breast Cancer

Actively Recruiting

1 location

A Phase 1-2 Dose-escalation and Expansion Study of ST316 in ...

Colon Cancer

Actively Recruiting

11 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here